Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Arvinas Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
ARVN
Nasdaq
8731
https://www.arvinas.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Arvinas Inc
Arvinas, Inc. (ARVN) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
- Apr 26th, 2024 2:00 pm
Arvinas Appoints Randy Teel, Ph.D., as Chief Business Officer
- Apr 24th, 2024 8:30 pm
Novartis (NVS) Inks Deal for ARVN's Prostate Cancer Candidate
- Apr 12th, 2024 5:55 pm
Biotech Stocks Heat Up As Arvinas Scores Novartis Licensing Pact, Janux Reportedly Explores Options
- Apr 11th, 2024 8:19 pm
UPDATE 2-Novartis taps Arvinas' cancer drug for up to $1 billion
- Apr 11th, 2024 11:40 am
Arvinas Enters into a Transaction with Novartis, including a Global License Agreement for the Development and Commercialization of PROTAC® Androgen Receptor (AR) Protein Degrader ARV-766 for the Treatment of Prostate Cancer
- Apr 11th, 2024 11:00 am
Is Arvinas (ARVN) Stock a Solid Choice Right Now?
- Apr 9th, 2024 12:48 pm
Arvinas Appoints Noah Berkowitz, M.D., Ph.D., as Chief Medical Officer
- Mar 18th, 2024 8:40 pm
Arvinas to Participate in Upcoming Investor Conferences
- Mar 4th, 2024 12:00 pm
Arvinas, Inc. (NASDAQ:ARVN) Just Reported Yearly Earnings: Have Analysts Changed Their Mind On The Stock?
- Mar 1st, 2024 10:21 am
Is a Surprise Coming for Arvinas (ARVN) This Earnings Season?
- Feb 28th, 2024 1:30 pm
Arvinas, Inc. (ARVN) Reports Q4 Loss, Misses Revenue Estimates
- Feb 27th, 2024 1:30 pm
Arvinas Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
- Feb 27th, 2024 12:00 pm
Arvinas (NASDAQ:ARVN) shareholders are still up 143% over 5 years despite pulling back 10% in the past week
- Feb 24th, 2024 1:13 pm
Wall Street Analysts See a 30.21% Upside in Arvinas, Inc. (ARVN): Can the Stock Really Move This High?
- Feb 23rd, 2024 2:55 pm
What Makes Arvinas, Inc. (ARVN) a Strong Momentum Stock: Buy Now?
- Feb 21st, 2024 5:00 pm
Arvinas Announces Chief Financial Officer Transition
- Feb 20th, 2024 9:05 pm
Arvinas Announces First-in-Human Dosing of ARV-102, an Investigational PROTAC® Protein Degrader for Neurodegenerative Disease
- Feb 20th, 2024 12:00 pm
Carrick Therapeutics Announces First Patient Dosed in Phase 1b/2 Clinical Trial of Samuraciclib in Combination with Vepdegestrant in Patients with Advanced Breast Cancer
- Feb 14th, 2024 1:00 pm
Goldman Sachs Predicts at Least 45% Rally for These 2 ‘Strong Buy’ Stocks — Here’s Why They Have Solid Upside
- Feb 8th, 2024 1:26 pm
Scroll